Ultime notizie per CareMax (OTC:CMAXQ) Azioni

CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.

CareMax Inc

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Thursday.
Shares of Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/25/04/44853254/alcoa-shares-gain-after-mixed-q1-results-eps-beat-revenues-miss">first-quarter results</a>.
Alcoa reported quarterly earnings of $2.15 per share, which beat the analyst consensus estimate of $1.70. Quarterly revenue came in at $3.37 billion, which missed the analyst consensus estimate of $3.53 billion and is an increase over revenue of $2.6 billion from the same period last year.
Alcoa shares dipped 2.6% to $24.43 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Sionna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>) shares tumbled 30% to $7.00 in pre-market trading following a 5% gain on Wednesday.</li>
<li>Mercer International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) shares dipped 20.4% to $4.10 in pre-market trading. Mercer International will release its first quarter results for the period ending March 31, 2025 on Thursday, May 1, after the closing bell.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 15.5% to $2.40 in pre-market trading.</li>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) fell 14.4% to $5.01 in pre-market trading after gaining around 6% on Wednesday.</li>
<li>Liberty Latin America Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILAK#NASDAQ">LILAK</a>) dipped 11.4% to $4.61 in pre-market trading.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares fell 8.7% to $17.01 in pre-market trading.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) fell 7.4% to $13.20 in pre-market trading as the company announced the pricing of common stock offering.</li>
<li>TransAlta Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAC#NYSE">TAC</a>) fell 6.3% to $8.12 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44836659/top-3-industrials-stocks-that-may-plunge-this-month">Top 3 Industrials Stocks That May Plunge This Month</a> </li>
</ul>
Photo via Shutterstock

News

Pre-Market Outlook

Markets

Movers

CURV

INNV

LILAK

MERC

SION

TILE

Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Piper Sandler analyst Michael Lavery maintains Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) with a Overweight and raises the price target from $43 to $44.

Price Target

Analyst Ratings

CELH

Piper Sandler Maintains Overweight on Celsius Holdings, Raises Price Target to $44

Macro Economic Events

Global

Economics

ECB Cuts Refi Rate From 2.65% To 2.4%, Cuts Deposit Facility Rate From 2.5% To 2.25%

European certification for PD-L1 IHC 22C3 pharmDx to help gastric or GEJ adenocarcinoma patients for KEYTRUDA&#xAE; therapy
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agilent.com&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=Agilent+Technologies+Inc.&amp;index=1&amp;md5=189415f0603bad84f35737c63c76e8f5">Agilent Technologies Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) today announced its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agilent.com%2Fen-us%2Fproduct%2Fpharmdx%2Fpd-l1-ihc-22c3-pharmdx%2Fpd-l1-ihc-22c3-pharmdx-product-page&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=PD-L1+IHC+22C3+pharmDx&amp;index=2&amp;md5=21cf51e6b3279e302118ed584b1c2264">PD-L1 IHC 22C3 pharmDx</a> (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.keytrudahcp.com%2F&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=KEYTRUDA%26%23174%3B&amp;index=3&amp;md5=0c3043ee2dca3cb48ea79aaa891d2630">KEYTRUDA&#xAE;</a> (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. KEYTRUDA is an anti-PD-1 therapy developed by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2F&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=Merck&amp;index=4&amp;md5=d752f5b3ee034d4f80798653f8ac39a7">Merck</a> (known as MSD outside the United States and Canada).
In addition to gastric or GEJ adenocarcinoma, PD-L1 IHC 22C3 pharmDx is IVDR certified as an aid in identifying non-small cell lung cancer (NSCLC), urothelial carcinoma, esophageal cancer, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), and cervical cancer patients for treatment with KEYTRUDA. Consequently, PD-L1 IHC 22C3 pharmDx is labeled for seven cancer indications and is the only IVDR-certified CDx to identify gastric and GEJ adenocarcinoma patients for treatment with KEYTRUDA.

Agilent Technologies Gets European Certification For PD-L1 IHC 22C3 pharmDx To Help Gastric Or GEJ Adenocarcinoma Patients for KEYTRUDA Therapy

U.S. President Donald Trump on Thursday lashed out at Federal Reserve Chair Jerome Powell on Tuesday, calling him "Too Late and Wrong" over the central bank's ongoing reluctance to cut interest rates, just as market forecasts increasingly price in a <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44850021/fed-chair-powell-says-crypto-and-banking-rules-will-loosen-as-sector-matures">prolonged Fed pause.</a>
What Happened: "The ECB is expected to cut interest rates for the 7th time," Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114352766082542122">posted </a>on social media. "And yet, ‘Too Late' Jerome Powell of the Fed, who is always TOO LATE AND WRONG, yesterday issued a report which was another, and typical, complete ‘mess!'"
Trump's tirade comes at a time when U.S. market participants, as tracked by Polymarket, are overwhelmingly betting on no change in the Fed's policy stance for its upcoming May 7 meeting. 
According to Polymarket odds, the <a href="https://polymarket.com/event/fed-decision-in-may-2025?tid=1744886504787">probability</a> of no change in rates sits at a commanding 88%, while just 10% expect a 25 basis point cut and only 2% foresee a more aggressive 50+ basis point reduction.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44849027/russia-reportedly-looking-into-creating-its-own-stablecoin">Russia Reportedly Looking Into Creating Its Own Stablecoin</a>
These expectations reflect widespread skepticism that Powell will move swiftly enough to ease financial conditions, despite signs of moderating inflation and Trump's claim that "oil prices are down, groceries (even eggs!) are down." 
Polymarket's data points to this belief, suggesting the Fed may stay on hold until at least the summer.
The president added that "the USA is getting RICH ON TARIFFS," and argued Powell "should have lowered interest rates, like the ECB, long ago." 
He concluded the post with a sharp warning: "Powell's termination cannot come fast enough!"
Why It Matters: This isn't Trump's first attack on the central banker he himself appointed in 2018.
But the criticism lands at a sensitive time, as markets navigate policy uncertainty, global trade tension, and a volatile macroeconomic backdrop.
According to Polymarket <a href="https://polymarket.com/event/will-trump-remove-jerome-powell">odds</a> as of Apr. 17, there's an 18% chance that Trump will remove Powell from his role by the end of 2025, a slight dip from earlier in the week but still notable amid growing political pressure.
The Fed's recent report, which Trump labeled a "complete mess," has not been detailed publicly, but the criticism underscores a long-standing rift between Trump and Powell, whom Trump appointed in 2018 but later frequently criticized during his presidency for not aligning monetary policy with his economic goals.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44845787/as-us-economy-resembles-emerging-market-bitcoin-is-more-mag-8-than-gold-mike-novogratz-says">As US Economy Resembles &#8216;Emerging Market&#8217;, Bitcoin Is More &#8216;MAG-8&#8217; Than Gold, Mike Novogratz Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Donald Trump Blasts 'Too Late And Wrong' Fed Chair Powell, But Polymarket Traders Doubt His 'Termination' Will Come 'Fast Enough'

Contracts

ACNT

Ascent Industries Signs Contract Expected To Generate Over $750K In Additional Annual EBITDA

Guidance

Utz Sees Q1 2025 Net Sales Growth 1.5%-1.7% YoY; Sees Adj. EPS $0.14-$0.16 Vs $0.14 Estimate

CLDI

Calidi Biotherapeutics Receives FDA Clearance Of IND Application For CLD-201 In Solid Tumors

SYDNEY, April 17, 2025 (GLOBE NEWSWIRE) -- Tilray Medical ("Tilray"), a division of Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>), a global company in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, has announced the availability of its medical cannabis edibles, Good Supply Pastilles, to patients in Australia. This launch marks Tilray Medical's first medical cannabis edible offering in the country, providing patients with a sugar-free and vegan-friendly treatment option.
Denise Faltischek, Chief Strategy Officer and Head of International, Tilray Brands, stated, "Our dedication to innovation and patient care drives us to continuously expand our offerings, ensuring that patients receive the best possible treatment options tailored to meet their needs and preferences. The expansion of our medical cannabis portfolio with the introduction of Good Supply Pastilles in Australia is a significant milestone for Tilray Medical. We are committed to providing high-quality, accessible medical cannabis products in convenient formats to patients worldwide."
Good Supply Pastilles are available in the following options:
<ul>
<li>Good Supply Pastilles THC10 (Strawberry)</li>
<li>Good Supply Pastilles THC10 CBD10 (Pineapple)</li>
<li>Good Supply Pastilles CBD20 (Raspberry) &nbsp;</li>
</ul>
Medical cannabis patients are now able to purchase the Good Supply Pastilles in packs of 60 from Tilray Direct or their local medical cannabis distributors.
Tilray continues to be a leading provider of EU-GMP certified medical cannabis to patients, physicians, pharmacies, hospitals, governments, and researchers globally. Today, Tilray offers a comprehensive portfolio of THC and CBD products in over 20 countries, supporting medical trials worldwide to study the efficacy of medical cannabis for various conditions.

TLRY

TSX:TLRY

Tilray Medical Announces Availability Of Medical Cannabis Edibles, Good Supply Pastilles, To Patients In Australia

<h3>Gainers</h3>
<ul>
<li>Unifi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) stock moved upwards by 22.3% to $5.65 during Thursday's pre-market session. The company's market cap stands at $103.6 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock rose 16.12% to $0.0. The company's market cap stands at $2.8 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares moved upwards by 13.63% to $0.14. The company's market cap stands at $6.8 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) stock rose 12.94% to $0.16. The market value of their outstanding shares is at $66.5 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares rose 9.54% to $0.97. The company's market cap stands at $18.6 million. </li>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) stock moved upwards by 8.42% to $0.26. The market value of their outstanding shares is at $2.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) shares fell 18.0% to $3.0 during Thursday's pre-market session. The company's market cap stands at $37.6 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) shares decreased by 13.13% to $2.3. The market value of their outstanding shares is at $3.4 million. </li>
<li>Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) stock declined by 8.97% to $1.32. The market value of their outstanding shares is at $156.7 million. </li>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) stock decreased by 8.37% to $2.41. The company's market cap stands at $59.9 million. </li>
<li>Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) stock decreased by 7.69% to $15.01. The market value of their outstanding shares is at $728.1 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) stock decreased by 6.49% to $0.75. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BALY

CULP

GNLN

NRDY

QVCGA

TOPW

VEEE

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) stock increased by 86.5% to $2.34 during Thursday's pre-market session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock rose 34.33% to $0.04. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock increased by 19.71% to $3.4. The market value of their outstanding shares is at $459.8 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock increased by 19.35% to $7.16. The market value of their outstanding shares is at $147.4 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares rose 14.75% to $1.4. The market value of their outstanding shares is at $5.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares rose 14.25% to $1.13. The company's market cap stands at $15.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares fell 36.0% to $1.26 during Thursday's pre-market session. The market value of their outstanding shares is at $39.3 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares decreased by 23.9% to $0.19. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) stock declined by 19.58% to $2.26. The company's market cap stands at $150.1 million. </li>
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock declined by 19.33% to $472.0. The company's market cap stands at $431.7 billion. As per the press release, Q1 earnings came out today. </li>
<li>Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) shares declined by 15.98% to $12.2. The company's market cap stands at $313.3 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) shares declined by 15.13% to $2.02. The company's market cap stands at $35.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHRO

FORA

NVNO

QNRX

SBFM

SOPH

STSS

SXTC

TNFA

TRML

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock increased by 13.5% to $0.75 during Thursday's pre-market session. The market value of their outstanding shares is at $9.4 million. </li>
<li>Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) shares rose 13.24% to $6.47. The company's market cap stands at $1.9 billion. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) stock rose 13.23% to $3.68. The market value of their outstanding shares is at $184.2 million. </li>
<li>Ideal Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPWR#NASDAQ">IPWR</a>) shares increased by 11.55% to $5.6. The market value of their outstanding shares is at $46.6 million. </li>
<li>Cycurion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) shares moved upwards by 10.55% to $0.46. The market value of their outstanding shares is at $5.4 million. </li>
<li>Orion Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) shares increased by 8.85% to $6.39. The company's market cap stands at $249.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) stock decreased by 12.3% to $0.33 during Thursday's pre-market session. The company's market cap stands at $26.5 million. </li>
<li>Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares fell 11.94% to $0.61. The company's market cap stands at $17.6 million. </li>
<li>ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) shares declined by 10.12% to $44.5. The company's market cap stands at $2.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) stock declined by 9.41% to $3.66. The market value of their outstanding shares is at $121.4 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares fell 7.83% to $1.06. The company's market cap stands at $128.1 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares decreased by 7.44% to $1.12. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTG

CYCU

ELPW

HTCO

IPDN

IPWR

LGCL

OMEX

UGRO

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares rose 72.3% to $0.37 during Thursday's pre-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares moved upwards by 47.94% to $2.16. The company's market cap stands at $2.5 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) stock increased by 15.41% to $0.82. The company's market cap stands at $8.6 million. </li>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) shares moved upwards by 12.18% to $1.48. The market value of their outstanding shares is at $12.1 million. </li>
<li>Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) stock moved upwards by 11.43% to $8.38. The company's market cap stands at $58.2 million. </li>
<li>Actelis Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) shares moved upwards by 10.47% to $0.69. The company's market cap stands at $5.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>QXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) stock declined by 9.3% to $12.94 during Thursday's pre-market session. The market value of their outstanding shares is at $5.2 billion. </li>
<li>WidePoint (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WYY#AMEX">WYY</a>) stock decreased by 8.75% to $2.4. The market value of their outstanding shares is at $23.5 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) stock fell 7.94% to $2.32. The market value of their outstanding shares is at $173.6 million. </li>
<li>Franklin Wireless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FKWL#NASDAQ">FKWL</a>) shares decreased by 7.78% to $4.51. The market value of their outstanding shares is at $53.1 million. </li>
<li>Syntec Optics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) shares fell 6.82% to $1.23. The market value of their outstanding shares is at $45.1 million. </li>
<li>ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) stock declined by 6.34% to $0.67. The market value of their outstanding shares is at $17.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

ARBB

ASNS

FKWL

IFBD

OPTX

SLNH

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

Earnings

Cycurion FY24 Revenues $17.8M vs $19.35M YoY; EPS $0.01 vs $(0.14) YoY

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=enUbUY5_QZwJp_8KN6336lY1IB1ulJx95BWFgrcVl5jC3L4RVRNvTx6gaBSkE_ynFCK_In3ODIR5MaPchbZ6Fg==">LifeMD, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>), a leading provider of virtual primary care services, today announced expanded acceptance of insurance to Medicare beneficiaries for qualifying care. Initially available to more than 21 million Medicare Part B beneficiaries in 26 states, the company expects to expand access to medically necessary services for more than 60 million Medicare beneficiaries nationwide, with access to qualifying services across 49 states anticipated by the end of the second quarter.

LFMD

Lifemd Announces Expanded Acceptance Of Insurance To Medicare Beneficiaries For Qualifying Care

Biotech

General

ALEC

Alector Completes Enrollment In PROGRESS-AD Phase 2 Clinical Trial If AL101/GSK4527226 For Individuals With Early Alzheimer's Disease

Scrambling to submit your taxes even after the April 15 deadline? <a href="https://www.benzinga.com/money/how-to-file-your-own-taxes">Filing for an extension</a> can be a lifesaver if you're juggling personal obligations or wrestling with intricate returns. Rather than rushing, you can secure six extra months to organize your finances and file without penalty.
<h4 class="wp-block-heading">Why Bother With An Extension?</h4>
Not everyone can meet the IRS's recommendation to file early. Unexpected life events, delayed documents, or a complicated tax situation might slow you down. An extension buys you breathing room until October 15, letting you gather all your paperwork without incurring a "failure to file" penalty.
<h4 class="wp-block-heading">Who Gets More Time Automatically?</h4>
Certain exceptions already exist according to the IRS website. If you're on active military duty in a <a href="https://www.irs.gov/individuals/military/combat-zones">combat zone</a>, you get 180 days after leaving that area to file. Americans <a href="https://www.irs.gov/individuals/international-taxpayers/us-citizens-and-resident-aliens-abroad-automatic-2-month-extension-of-time-to-file">living abroad</a> or stationed overseas also receive an automatic two-month extension. Meanwhile, residents in states <a href="https://www.irs.gov/newsroom/tax-relief-in-disaster-situations">affected by natural disasters</a> can receive extra filing time, sometimes until November 3.
See also: <a href="https://www.benzinga.com/25/04/44855064/trump-administration-asks-irs-to-revoke-harvards-tax-exempt-status-after-president-accuses-ivy-league-university-of-pushing-sickness">Trump Administration Asks IRS To Revoke Harvard&#8217;s Tax-Exempt Status After President Accuses Ivy League University Of Pushing &#8216;Sickness&#8217;</a>
<h4 class="wp-block-heading">How To File For An Extension Online?</h4>
To request an extension, use the IRS's online payment system: Simply check the box indicating you need extra time. Alternatively, you can e-file <a href="https://www.irs.gov/forms-pubs/about-form-4868">Form 4868</a> (Application for Automatic Extension of Time to File U.S. Individual Income Tax Return), which just asks for your basic personal information. Both options give you a quick, digital route to notification-free breathing space.
<h4 class="wp-block-heading">Your Payment Will Still Be Due</h4>
An extension shifts your paperwork deadline, not your tax bill due date. If you owe money, estimate the total, then pay by April 15 to dodge the "failure to pay" penalty. Missing the payment deadline could saddle you with monthly fees, ultimately capping at <a href="https://www.irs.gov/newsroom/taxpayers-should-file-their-tax-return-on-time-to-avoid-costly-interest-and-penalty-fees">25% of your unpaid taxes</a>.
<h4 class="wp-block-heading">Can't Pay Your Tax Bill?</h4>
If you're short on cash, the IRS offers both short-term and long-term <a href="https://www.irs.gov/payments/payment-plans-installment-agreements">payment plans</a>. You can apply online, and if you can show "reasonable cause" for late or partial payments, you might avoid some penalties. The main thing is to communicate with the IRS early, so you stay in good standing.
Read next: <a href="https://www.benzinga.com/government/regulations/25/04/44731006/when-are-your-deposits-flagged-understanding-how-and-why-banks-report-transactions-to-the-irs">When Are Your Deposits Flagged? Understanding How And Why Banks Report Transactions To The IRS</a>

Financing

Legal

Personal Finance

Running Late On Your Return? How To Secure A No-Penalty Tax Extension

Management

Utz Appoints William J. Kelley Jr. As CFO, Effective May 1, 2025

Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications
NEW YORK, April 17, 2025 /PRNewswire/ --&nbsp;Hoth Therapeutics, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics.
The newly issued patent secures broad claims covering antisense oligomers that target the&nbsp;KIT&nbsp;gene — a clinically validated oncogene associated with gastrointestinal stromal tumors (GIST), leukemia, mastocytosis, and other cancers. These oligomers are designed to alter pre-mRNA splicing or reduce KIT protein expression, offering a highly targeted therapeutic mechanism.
"This patent significantly strengthens Hoth's position in the RNA therapeutics space and marks a major milestone in our global strategy,"&nbsp;said&nbsp;Robb Knie, CEO of Hoth Therapeutics.&nbsp;"Targeting the KIT pathway with antisense technology represents a precision-driven approach that holds immense potential in oncology and beyond. This grant provides strong validation and global momentum as we continue advancing our RNA platform toward the clinic."

HOTH

Hoth Therapeutics Granted Japanese Patent Expanding Global Intellectual Property Portfolio In RNA-based Cancer Therapeutics

Wells Fargo initiates coverage on Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Equal-Weight rating and announces Price Target of $4.

Initiation

RLAY

Wells Fargo Initiates Coverage On Relay Therapeutics with Equal-Weight Rating, Announces Price Target of $4

CareMax

Comments

CareMax

Notizie

Ultime notizie per CareMax (OTC:CMAXQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO